semaglutide + NNC0480-0389

A combination drug consisting of **semaglutide**, a glucagon-like peptide-1 (GLP-1) receptor agonist, and **NNC0480-0389**, a novel glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, under investigation for the treatment of type 2 diabetes. Semaglutide enhances insulin secretion and suppresses glucagon release, thereby lowering blood sugar levels. NNC0480-0389 mimics the action of GIP, another gut-derived incretin hormone, and is intended to complement the action of semaglutide by targeting distinct points in glucose regulation. This fixed-dose combination is being tested primarily by **Novo Nordisk** in phase 2 clinical studies as a subcutaneous injection for improving glycemic control in adults with type 2 diabetes. Early results show improved efficacy versus placebo or GIPRA monotherapy, with a safety profile similar to the individual agents[1][3][6].

Brand names

OzempicWegovyRybelsus

Other names

semaglutide